Selective disruption of DNMT1/ELK1 interactions induces DGKI re-expression and promotes temozolomide sensitivity of MGMT methylated/DGKI methylated glioblastoma

Abstract Background DNA methyltransferase (DNMT) inhibitors are emerging as a promising class of agents for personalized and targeted cancer therapy, particularly in malignancies with limited therapeutic options such as glioblastoma (GB). In GB, the MGMT/DGKI methylation profile serves as a biomarke...

Full description

Bibliographic Details

Published in:	Clinical Epigenetics
Main Authors:	Jean-Maxime Besson, Amandine Etcheverry, Arulraj Nadaradjane, Gwenola Bougras-Cartron, Marc Aubry, Jean-Sebastien Frenel, Alain Chevanieu, Marie Lopez, Jean Mosser, Pierre-François Cartron
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Subjects:	Epidrug Protein–protein interaction Peptide DNMT1 ELK1
Online Access:	https://doi.org/10.1186/s13148-025-01943-8